EGFR and adenocarcinoma: PD-L1 status (positive vs. negative) was not associated with clinical parameters, including age (<70 vs. ≥70, p = 1.000), sex (male vs. female, p = 1.000), smoking history (yes vs. no, p = 0.211), histology (adenocarcinoma vs. others, p = 0.276), EGFR mutation (Exon 19 del vs. Exon 21 L858R vs. others, p = 0.789), PS (0–1 vs. ≥2, p = 0.716), LDH (<200 IU/L vs. ≥200 IU/L, p = 0.130), brain metastasis (yes vs. no, p = 0.759), and stage (IIIA-C/IVA vs. IVB, p = 1.000) (Fisher’s exact test).